- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Kylin Therapeutics, Inc., a developer of next-generation RNAi therapeutics, announced the expansion of its research and development efforts. The project will advance promising new RNAi cancer therapies. This expanded effort will be conducted at Purdue University's Bindley Bioscience Center, and will focus on further validating targeted, systemically delivered cancer therapies utilizing Kylin's proprietary pRNAi platform. "Our in vivo efforts have shown pRNAi to be a very potent and versatile RNA inducing platform," said Eric Davis, the president and CEO of Kylin. "This expanded effort will enable us to test the flexibility of the pRNAi platform against various cancer targets."
About Kylin Therapeutics, Inc.
Kylin Therapeutics, Inc. is a biotechnology company focused on the development of a novel platform technology called pRNA. pRNA is a discrete, RNA-based nanoparticle system. Kylin has re-engineered pRNA to induce RNA interference (RNAi). The resulting therapeutic platform is called pRNAi. This platform represents the next generation of RNAi-inducing therapeutics with superior pharmacokinetics and potency over siRNA.
For more information, please click here
Kylin Therapeutics, Inc.
Eric Davis, President and CEO
Copyright © GlobeNewswire, Inc.If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
European Technology Platform for Nanomedicine and ENATRANS European Consortium Launch the 2nd edition of the Nanomedicine Award: The Award to be presented at BIO-Europe conference in Munich, November 2015 July 30th, 2015
Take a trip through the brain July 30th, 2015
Sol-gel capacitor dielectric offers record-high energy storage July 30th, 2015